Post by Swiss Re

⚕️Overdiagnosis reveals the trade-offs of earlier cancer detection. Detecting cancer sooner can save lives, improve outcomes and expand treatment options. But advances in screening and diagnostics can also detect signals of disease that may never have caused symptoms or harm. This is known as overdiagnosis: the detection of low-risk or indolent conditions. As AI and multi-cancer early detection (MCED) tests expand, overdiagnosis is becoming increasingly relevant in cancer detection. In some cancers, such as thyroid cancer, as many as 3 in 4 detected cases may not have been cause for concern. For individuals this will likely involve follow-up testing, adding to both a physical, emotional and financial burden. For insurers, understanding evolving cancer diagnostics is becoming essential for sustainable underwriting, pricing and product design. Managing this shift will become increasingly important as cancer risk continues to evolve. Learn more about overdiagnosis in our latest L&H Reinsurance publication, Reshaping Cancer Detection:🔗 https://ow.ly/T8hw50Zh7VB 🕮 Term by Term. Breaking down risk language, one term at a time.